President Trump was talking to reporters Friday after Dr. Oz's swearing-in ceremony when the news conference abruptly ended.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

"We are proud to announce that LifeMD now accepts Medicare Fee-For-Service for qualifying virtual primary care, including such care provided in our weight management program – an important step ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

“Currently, Medicare covers these drugs only under specific circumstances ... “Having said that, these weight-loss drugs ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

It's little secret that America has a weight problem. For decades, Americans have embraced and abandoned countless ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

The Centres for Medicare and Medicaid Services (CMS) said late on Friday that it would not cover anti-obesity medicines (AOMs) like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...